SIGA is a leader in global health, developing medicines to prevent and treat emerging infectious diseases with high unmet medical needs.

Infectious diseases pose an imminent and severe threat to global health that cannot be adequately addressed with vaccines alone. Smallpox, monkeypox (sometimes referred to as mpox), and other orthopoxviruses are particularly worrisome because they are highly infectious and deadly. We are developing best-in-class products to treat these infections in patients worldwide.  

​

Society must take proactive steps to prevent and stop outbreaks – whether natural, accidental, or intentional. We are committed to partnering with governments, commercial organizations, foundations, and others who share in the responsibility of global health security. ​